GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Almujtama Alraida Medical Co SJSC 9592.SR · SAR

N/A · Tadawul · 🇸🇦 Saudi Arabia

Compare

19.70

—

Close of 4 Nov 2026, in SAR

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in SAR, from our data supplier.

FY2025

Revenue

SAR 454.7m

FY2021FY2025

Net income

SAR 8.4m

FY2021FY2025

Free cash flow

SAR 25.0m

FY2021FY2025

Shareholders' equity

SAR 126.3m

FY2021FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021
RevenueSAR 454.7mSAR 430.8mSAR 407.7mSAR 367.1mSAR 304.5m
Gross profitSAR 149.7mSAR 142.1mSAR 129.2mSAR 96.7mSAR 61.6m
Operating incomeSAR 10.7mSAR 9.3mSAR 13.9mSAR 25.7mSAR 9.9m
Net incomeSAR 8.4mSAR 7.9mSAR 11.4mSAR 19.1mSAR 7.8m
Diluted earnings per share0.870.831.202.010.81

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021
Total assetsSAR 515.1mSAR 459.5mSAR 442.0mSAR 334.4mSAR 303.2m
Cash and short-term investments—SAR 2.2mSAR 13.0mSAR 4.1mSAR 4.2m
Total liabilitiesSAR 388.8mSAR 321.3mSAR 312.2mSAR 215.8mSAR 294.5m
Debt—SAR 170.4mSAR 168.9mSAR 123.1mSAR 117.9m
Shareholders' equitySAR 126.3mSAR 138.1mSAR 129.8mSAR 118.6mSAR 8.7m
Shares outstanding10m10m10m10m10m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021
Cash from operationsSAR 25.0mSAR 51.4mSAR 68.1mSAR 18.5mSAR 17.3m
Capital spending—−SAR 28.2m−SAR 40.4m−SAR 19.6m−SAR 7.3m
Free cash flowSAR 25.0mSAR 23.2mSAR 27.7m−SAR 1.0mSAR 9.9m

Latest quarters

By quarter end

Dec 2025Jun 2025Dec 2024Jun 2024Dec 2023Jun 2023Dec 2022Jun 2022
RevenueSAR 219.7mSAR 235.0mSAR 221.4mSAR 209.4mSAR 203.6mSAR 204.1mSAR 195.3mSAR 171.8m
Gross profitSAR 74.4mSAR 75.3mSAR 51.5mSAR 49.4mSAR 46.7mSAR 53.0mSAR 53.2mSAR 43.5m
Operating incomeSAR 74.4mSAR 75.3mSAR 4.9mSAR 3.6mSAR 786,660SAR 13.2mSAR 14.6mSAR 9.5m
Net incomeSAR 4.1mSAR 4.3mSAR 5.9mSAR 2.0mSAR 60,475SAR 11.3mSAR 12.2mSAR 6.8m
Diluted earnings per share0.430.440.620.210.011.191.290.72
Cash from operations——SAR 27.0mSAR 24.0mSAR 22.0mSAR 45.0m−SAR 5.0mSAR 23.0m
Capital spending——−SAR 16.0m−SAR 11.0m−SAR 15.0m−SAR 24.0m−SAR 11.0m−SAR 8.0m
Free cash flow——SAR 11.0mSAR 13.0mSAR 7.0mSAR 21.0m−SAR 16.0mSAR 15.0m
Total assetsSAR 515.1mSAR 507.0mSAR 459.5mSAR 473.1mSAR 442.0mSAR 405.1mSAR 334.4m—
Cash and short-term investments—SAR 6.8mSAR 2.2mSAR 7.3mSAR 13.0mSAR 7.4mSAR 4.1m—
Debt—SAR 37.5mSAR 61.1mSAR 28.9mSAR 28.3mSAR 22.8mSAR 20.2m—
Shareholders' equitySAR 126.3mSAR 142.4mSAR 138.1mSAR 131.8mSAR 129.8mSAR 129.6mSAR 118.6m—

Growth per year

Compound annual rate

3 years5 years10 years
Revenue7.4%——
Operating income-25.3%——
Net income-23.9%——

Average margins

Over each period

1 year3 years5 years10 years
Gross margin33.0%31.2%——

Valuation history

At each fiscal year end

FY2025FY2024FY2023
Price to earnings34.037.225.0
Price to sales0.60.70.7

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.